Ziprasidone in Parkinson's Disease Psychosis [2]

Canadian Journal of Psychiatry

Volumn 49, Issue 1, 2004, Pages 73-

  Connemann, Bernhard J ^a   Schönfeldt Lecuona, Carlos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; CARBIDOPA; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ENTACAPONE; LEVODOPA; NEUROLEPTIC AGENT; QUETIAPINE; ZIPRASIDONE;

AGED; AGRANULOCYTOSIS; AKATHISIA; AUDITORY HALLUCINATION; CASE REPORT; DELUSION; DOSE RESPONSE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERKINESIA; LETTER; MALE; MYOCLONUS; PARKINSON DISEASE; PSYCHOSIS; VISUAL HALLUCINATION;

EID: 0842321863     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900119     Document Type: Letter

References (3)

1. Arato M, O'Connor R, Meltzer HY; ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-15.
2. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
3. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-8.